We are Roche
Through our 125-year history, we have grown into one of the world’s largest pharmaceutical companies.
We turn today’s science into tomorrow’s solutions, so our patients can live longer, better lives.
#125Years of Celebrating Life!
Celebrate Life is an embodiment of our past glories, pioneering spirit and future achievements. It is a reinforcement of our purpose of ‘Doing now what patients need next’. This is our 125-year legacy. It is also our promise for the future. In 2021, we celebrate our history, our culture and the enduring purpose that guides Roche’s next 125 years toward a sustainable, healthy future.
The Blue Tree Program: because no one should have to battle a disease alone.
Affordability and accessibility challenges shouldn’t be barriers for receiving quality healthcare. Roche Pharma India’s patient assistance program - The Blue Tree addresses different barriers in the healthcare system and provides patients with sustainable solutions— right from diagnosis until the completion of their treatment.
Nilofer Randeria: More than just a patient— a survivor; a fighter.
Nilofer Randeria from Surat, a breast cancer survivor, is an inspiration to everyone. Watch this video as Nilofer candidly talks about her battle with breast cancer to emerge victorious! #HERConnectionIndia
PHESGO – the world's first fixed dose combination of two monoclonal antibodies in Oncology for the treatment of HER-2 positive breast cancer, now available in India.
PHESGO aims to foster efficiency in the Indian healthcare ecosystem, and improve the quality of life of patients by reducing the in-clinic time by up to 90%. PHESGO combines two proven blockbuster monoclonal antibodies: Perjeta® (pertuzumab) and Herceptin® (trastuzumab) in a single vial for subcutaneous form of administration. PHESGO’s launch in India is a historic milestone and can revolutionize the HER-2 positive breast cancer treatment landscape, at 20% lesser cost to the society.
Medical experts view the SEC recommendation for Tecentriq for metastatic urothelial cancer as a promising development for cancer patients in the country.
Central Drugs Standard Control Organization (CDSCO) Subject Expert Committee (SEC) has recommended that there is no objection for change in indication of Tecentriq in locally advanced or metastatic bladder cancer known medically as urothelial carcinoma indication. This according to the regulatory authority is in line with US FDA approvals.
